A phase I/II study of pembrolizumab in combination with nab-paclitaxel in patients with unresectable stage III or stage IV non small-cell lung carcinoma (NSCLC) by Rami Nassabein, Pierre-Olivier Gaudreau, Wiam Belkaid, Marie Florescu, Normand Blais

Get full text

A study of the efficacy and toxicity outcomes of extended durvalumab dosing in patients with stage III unresectable non-small cell lung cancer (NSCLC) during the COVID-19 pandemic by Lilian Hanna, Gordon Taylor Moffat, Wilma Hopman, Pierre-Olivier Gaudreau, Andrea S. Fung

Get full text

iRECIST and atypical patterns of response to immuno-oncology drugs by Emiliano Calvo, Sabine Schmid, Jorge Luis Ramon-Patino, Sally Lau, Lesley Seymour, Pierre-Olivier Gaudreau, Janice Juan Ning Li, Penelope Ann Bradbury

Get full text

Prospective Evaluation of Fetal Hemoglobin Expression in Maternal Erythrocytes: An Analysis of a Cohort of 345 Parturients by Laurence Blain, Christian Watier, Xiaoduan Weng, Andre Masse, Marie-Josée Bédard, Nazila Bettache, Florence Weber, Michele Mahone, Stéphanie Forté, Vincent-Philippe Lavallée, Pierre-Olivier Gaudreau, Michael J. Newmarch, Denis Soulières

Get full text

WISP1 is associated to advanced disease, EMT and an inflamed tumor microenvironment in multiple solid tumors by Pierre-Olivier Gaudreau, Sylvie Clairefond, Caleb A. Class, Pierre-Luc Boulay, Pavel Chrobak, Bertrand Allard, Feryel Azzi, Sandra Pommey, Kim-Anh Do, Fred Saad, Dominique Trudel, Marian Young, John Stagg

Get full text